查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1766079

全球腦炎藥物市場：預測至 2032 年－按疾病類型、給藥途徑、病原體、通路、最終用戶和地區進行分析

Encephalitis Treatment Market Forecasts to 2032 - Global Analysis By Disease Type (Primary encephalitis and Secondary encephalitis), Route of Administration, Causative Agent, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

據 Stratistics MRC 稱，2025 年全球腦炎藥物市場價值為 239 億美元，預計到 2032 年將達到 389 億美元，預測期內的複合年成長率為 7.2%。腦炎藥物是指針對腦炎的醫療管理和治療性介入。腦炎是一種腦部炎症，通常由病毒感染引起，但也可能由細菌、真菌或自體免疫原因引起。治療旨在減少腦部發炎、控制症狀和預防併發症。通常會提供支持性治療，包括抗病毒藥物和抗生素、減輕腫脹的皮質類固醇、用於抽搐的抗驚厥藥物以及補液和氧氣療法。在嚴重的情況下，可能需要住院和加護治療。早期診斷和及時治療對於最大限度地減少長期神經病變和改善患者預後至關重要，特別是對於兒童和老年人等弱勢群體。

據國家感染疾病控制中心稱，日本腦炎是印度的一個主要健康問題。

病毒性腦炎發生率上升

病毒性腦炎發生率的上升正對腦炎藥物市場產生積極影響，推動了對先進診斷工具、抗病毒療法和支持性護理解決方案的需求。認知度的提高和早期診斷促使醫療保健提供者投資於更優的治療通訊協定，從而促進了市場成長。此外，政府和醫療機構正在資助研發，以改善治療效果。因此，對及時有效管理腦炎的日益重視正激勵製藥公司進行創新，進一步拓寬市場前景。

醫療費用高昂

腦炎治療費用高昂是市場成長的主要障礙，尤其是中低收入地區。昂貴的抗病毒藥物、加護治療、長期住院和復健服務給患者和醫療保健系統帶來了經濟負擔，阻礙了及時診斷和治療，導致干預延遲和預後不良。因此，經濟障礙限制了患者獲得先進治療方案的機會，限制了市場擴張，並為醫療保健提供者帶來了重大挑戰。

診斷和治療的進展

診斷和治療方法的進步極大地推動了市場的成長。快速且準確的診斷工具的發展使得早期發現成為可能，從而改善了治療效果。抗病毒和免疫調節療法的創新正在提高患者的康復率並減少長期併發症。個人化醫療和基於生物標記的治療正在進一步完善治療方法。這些進步不僅提高了臨床效率，還鼓勵增加研究投入，最終擴大市場規模並改善全球腦炎患者的照護。

複雜診斷

腦炎診斷複雜且耗時，對治療市場構成重大挑戰。診斷延遲或不準確會導致治療延遲、患者預後惡化並增加併發症風險。由於缺乏先進診斷工具，尤其是在資源匱乏的地區，早期發現也受到阻礙。這種複雜性增加了醫療成本，阻礙了及時干預，從而限制了市場成長，從而影響了腦炎治療方案的整體有效性。

COVID-19的影響

COVID-19 疫情對醫療體系造成巨大壓力，並將資源重新用於病毒防治，擾亂了腦炎治療市場。診斷延遲、就診人數減少以及臨床試驗中斷，影響了及時治療。然而，隨著人們對 COVID-19 相關神經系統併發症的認知不斷提高，腦炎研究也重新受到關注。這種雙重影響為腦炎診斷和治療的發展帶來了短期挑戰和長期機會。

預計病毒部分在預測期內將是最大的。

由於單純皰疹病毒、日本腦炎和西尼羅河病毒等病毒感染疾病的流行，預計病毒學領域將在預測期內佔據最大的市場佔有率。病毒性腦炎認知度的提高和早期診斷的提高，推動了對有效抗病毒藥物和支持性治療的需求。此外，政府在疫苗接種和疫情控制方面的措施和資金投入也促進了市場擴張。控制病毒性腦炎疫情的迫切性進一步加速了先進腦炎治療方案的研究、開發和應用。

抗生素領域預計在預測期內以最高複合年成長率成長

抗生素領域預計將在預測期內實現最高成長，因為它能夠有效治療細菌性腦炎，尤其是在次發性腦炎病例中。醫療保健提供者的認知度不斷提高以及針對性抗生素治療的進步正在推動需求成長。此外，頻譜抗生素和診斷工具的日益普及使得及時治療成為可能，減少了併發症，並提高了患者的康復率。這些因素共同推動了市場擴張，使抗生素成為腦炎藥物策略的重要組成部分。

比最大的地區

在預測期內，亞太地區預計將佔據最大的市場佔有率，這得益於醫療保健意識的不斷增強、病毒感染疾病的流行以及先進醫療設施的普及。政府加強醫療基礎設施和擴大疫苗接種計劃的措施正在進一步推動市場擴張。此外，研發投入的增加以及有效抗病毒療法的普及也有助於改善治療效果。人口成長和對更優質神經系統護理的需求也在推動該地區市場的成長。

複合年成長率最高的地區：

預計北美地區在預測期內的複合年成長率最高。這得歸功於人們日益增強的認知度以及蚊媒病毒感染疾病和疾病引起的腦炎病例的不斷增加。強而有力的政府舉措和科研資金推動了研發和早期診斷的增加。該地區受益於最尖端科技的獲取以及大型製藥公司的所在地。此外，由於對高效抗病毒治療和疫苗的需求日益成長，美國和加拿大的市場也在不斷擴張。

免費客製化服務

本報告的所有訂閱者均可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他公司（最多 3 家）進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 簡介

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 主要研究資料
    • 二手研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 介紹
  • 驅動程式
  • 限制因素
  • 市場機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 企業之間的競爭

第5章全球腦炎藥物市場（依疾病類型）

  • 原發性腦炎
  • 次發性腦炎

6. 全球腦炎治療市場（按治療劑）

  • 抗病毒藥物
  • 類固醇注射
  • 抗生素
  • 免疫球蛋白治療
  • 血漿置換
  • 其他治療方法

7. 全球腦炎藥物市場（依給藥途徑）

  • 口服藥物
  • 腸外藥物
  • 其他給藥途徑

8. 全球腦炎藥物市場（按病原體）

  • 病毒性的
  • 自體免疫
  • 細菌
  • 其他病原體

9. 全球腦炎藥物市場（按分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 10 章全球腦炎藥物市場（按最終用戶）

  • 醫院
  • 研究中心
  • 診所
  • 專業中心
  • 其他最終用戶

第 11 章全球腦炎藥物市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併與收購（M&A）
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司概況

  • Pfizer Inc.
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc（GSK）
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Abbott Laboratories
  • Basilea Pharmaceutica Ltd.
  • Melinta Therapeutics LLC
  • Bristol Myers Squibb
  • Novartis AG
  • Johnson & Johnson
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Limited
  • Aurobindo Pharma Limited
  • Hikma Pharmaceuticals PLC
  • Valneva SE
  • Bharat Biotech
  • BIKEN
  • Substipharm
Product Code: SMRC29934

According to Stratistics MRC, the Global Encephalitis Treatment Market is accounted for $23.9 billion in 2025 and is expected to reach $38.9 billion by 2032 growing at a CAGR of 7.2% during the forecast period. Encephalitis treatment refers to the medical management and therapeutic interventions used to address encephalitis, an inflammation of the brain typically caused by viral infections, though bacterial, fungal, or autoimmune causes are also possible. Treatment aims to reduce brain inflammation, manage symptoms, and prevent complications. It often includes antiviral or antibiotic medications, corticosteroids to reduce swelling, anticonvulsants for seizures, and supportive care such as hydration and oxygen therapy. In severe cases, hospitalization and intensive care may be necessary. Early diagnosis and prompt treatment are crucial to minimize long-term neurological damage and improve patient outcomes, especially in vulnerable populations such as children and the elderly.

According to the National Center for Vector Borne Diseases Control, Japanese encephalitis is a significant health concern in India.

Market Dynamics:

Driver:

Rising Incidence of Viral Encephalitis

The rising incidence of viral encephalitis is positively impacting the encephalitis treatment market by driving demand for advanced diagnostic tools, antiviral therapies, and supportive care solutions. Increasing awareness and early diagnosis are pushing healthcare providers to invest in better treatment protocols, boosting market growth. Moreover, governments and healthcare institutions are funding research and development efforts to improve treatment efficacy. This growing focus on timely and effective management of encephalitis is encouraging pharmaceutical companies to innovate, further expanding the market landscape.

Restraint:

High Cost of Treatment

The high cost of encephalitis treatment significantly hampers market growth, especially in low- and middle-income regions. Expensive antiviral medications, intensive care, prolonged hospitalization, and rehabilitation services place a financial burden on patients and healthcare systems. This deters timely diagnosis and treatment, leading to delayed interventions and poor outcomes. As a result, the affordability barrier restricts access to advanced treatment options, limiting market expansion and posing a major challenge to healthcare providers.

Opportunity:

Advancements in Diagnostics & Therapeutics

Advancements in diagnostics and therapeutics are significantly driving growth in the market. The development of rapid and accurate diagnostic tools enables early detection, improving treatment outcomes. Innovations in antiviral and immunomodulatory therapies are enhancing patient recovery rates and reducing long-term complications. Personalized medicine and biomarker-based treatments are further refining therapeutic approaches. These advancements not only improve clinical efficiency but also encourage greater investment in research, ultimately expanding the market and offering improved care for encephalitis patients globally.

Threat:

Complex Diagnosis

The complex and time-consuming process of diagnosing encephalitis poses a significant challenge to the treatment market. Delayed or inaccurate diagnosis can lead to postponed treatment, worsening patient outcomes and increasing the risk of complications. Limited access to advanced diagnostic tools, especially in low-resource settings, further hampers early detection. This complexity restricts market growth by increasing healthcare costs and deterring timely intervention, thereby impacting the overall effectiveness of encephalitis treatment solutions.

Covid-19 Impact

The COVID-19 pandemic disrupted the encephalitis treatment market by straining healthcare systems and diverting resources toward managing the virus. Delays in diagnosis, reduced hospital visits, and interruptions in clinical trials affected timely treatment. However, increased awareness of neurological complications linked to COVID-19 also led to a renewed focus on encephalitis research. This dual impact created both short-term challenges and long-term opportunities for advancements in encephalitis diagnostics and therapies.

The viral segment is expected to be the largest during the forecast period

The viral segment is expected to account for the largest market share during the forecast period, due to rising prevalence of viral infections such as herpes simplex, Japanese encephalitis, and West Nile virus. Increasing awareness and early diagnosis of viral encephalitis have boosted the demand for effective antiviral drugs and supportive therapies. Moreover, government initiatives and funding for vaccination and outbreak control contribute to market expansion. The urgency to manage viral outbreaks further accelerates research, development, and adoption of advanced encephalitis treatment options.

The antibiotics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the antibiotics segment is predicted to witness the highest growth rate, as it offers effective solutions against bacterial causes of the disease, particularly in secondary encephalitis cases. Increased awareness among healthcare providers, advancements in targeted antibiotic therapies are driving demand. Additionally, the growing availability of broad-spectrum antibiotics and supportive diagnostic tools is enhancing timely treatment, reducing complications, and improving patient recovery rates. These factors collectively support market expansion and reinforce antibiotics as a critical component in encephalitis care strategies

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share owing to rising healthcare awareness, increasing prevalence of viral infections, and improved access to advanced medical facilities. Government initiatives aimed at strengthening healthcare infrastructure and expanding immunization programs are further supporting market expansion. Additionally, increasing investments in R&D and the availability of effective antiviral therapies are contributing to enhanced treatment outcomes. The growing population and demand for better neurological care are also fueling the region's market growth positively.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, because of growing awareness and an increase in encephalitis cases brought on by viral infections and illnesses spread by mosquitoes. Drug development and early diagnosis have increased because to strong government initiatives and research funding. The area gains by having access to cutting-edge technologies and being home to significant pharmaceutical enterprises. Furthermore, the market is expanding in the US and Canada due to rising need for efficient antiviral treatments and vaccinations.

Key players in the market

Some of the key players profiled in the Encephalitis Treatment Market include Pfizer Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc (GSK), Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Basilea Pharmaceutica Ltd., Melinta Therapeutics LLC, Bristol Myers Squibb, Novartis AG, Johnson & Johnson, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Pharma Limited, Hikma Pharmaceuticals PLC, Valneva SE, Bharat Biotech, BIKEN and Substipharm.

Key Developments:

In May 2025, Pfizer Inc. announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc., for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.

In October 2024, TRIANA Biomedicines, Inc. announced that it has entered into a strategic collaboration and licensing agreement with Pfizer to discover novel molecular glue degraders for multiple targets in several disease areas, including oncology.

Disease Types Covered:

  • Primary encephalitis
  • Secondary encephalitis

Treatments Covered:

  • Antiviral agents
  • Steroid injections
  • Antibiotics
  • Immunoglobulin therapy
  • Plasmapheresis
  • Other Treatments

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Other Routes of Administration

Causative Agents Covered:

  • Viral
  • Autoimmune
  • Bacterial
  • Pathogens

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

End Users Covered:

  • Hospitals
  • Research Centers
  • Clinics
  • Specialty Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Encephalitis Treatment Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Primary encephalitis
  • 5.3 Secondary encephalitis

6 Global Encephalitis Treatment Market, By Treatment

  • 6.1 Introduction
  • 6.2 Antiviral agents
  • 6.3 Steroid injections
  • 6.4 Antibiotics
  • 6.5 Immunoglobulin therapy
  • 6.6 Plasmapheresis
  • 6.7 Other Treatments

7 Global Encephalitis Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral
  • 7.4 Other Routes of Administration

8 Global Encephalitis Treatment Market, By Causative Agent

  • 8.1 Introduction
  • 8.2 Viral
  • 8.3 Autoimmune
  • 8.4 Bacterial
  • 8.5 Pathogens

9 Global Encephalitis Treatment Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Online Pharmacies
  • 9.4 Retail Pharmacies

10 Global Encephalitis Treatment Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Research Centers
  • 10.4 Clinics
  • 10.5 Specialty Centers
  • 10.6 Other End Users

11 Global Encephalitis Treatment Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Pfizer Inc.
  • 13.2 Sanofi S.A.
  • 13.3 F. Hoffmann-La Roche Ltd.
  • 13.4 GlaxoSmithKline plc (GSK)
  • 13.5 Merck & Co., Inc.
  • 13.6 Teva Pharmaceutical Industries Ltd.
  • 13.7 Abbott Laboratories
  • 13.8 Basilea Pharmaceutica Ltd.
  • 13.9 Melinta Therapeutics LLC
  • 13.10 Bristol Myers Squibb
  • 13.11 Novartis AG
  • 13.12 Johnson & Johnson
  • 13.13 Eli Lilly and Company
  • 13.14 Takeda Pharmaceutical Company Limited
  • 13.15 Aurobindo Pharma Limited
  • 13.16 Hikma Pharmaceuticals PLC
  • 13.17 Valneva SE
  • 13.18 Bharat Biotech
  • 13.19 BIKEN
  • 13.20 Substipharm

List of Tables

  • Table 1 Global Encephalitis Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Encephalitis Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 3 Global Encephalitis Treatment Market Outlook, By Primary encephalitis (2024-2032) ($MN)
  • Table 4 Global Encephalitis Treatment Market Outlook, By Secondary encephalitis (2024-2032) ($MN)
  • Table 5 Global Encephalitis Treatment Market Outlook, By Treatment (2024-2032) ($MN)
  • Table 6 Global Encephalitis Treatment Market Outlook, By Antiviral agents (2024-2032) ($MN)
  • Table 7 Global Encephalitis Treatment Market Outlook, By Steroid injections (2024-2032) ($MN)
  • Table 8 Global Encephalitis Treatment Market Outlook, By Antibiotics (2024-2032) ($MN)
  • Table 9 Global Encephalitis Treatment Market Outlook, By Immunoglobulin therapy (2024-2032) ($MN)
  • Table 10 Global Encephalitis Treatment Market Outlook, By Plasmapheresis (2024-2032) ($MN)
  • Table 11 Global Encephalitis Treatment Market Outlook, By Other Treatments (2024-2032) ($MN)
  • Table 12 Global Encephalitis Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 13 Global Encephalitis Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 14 Global Encephalitis Treatment Market Outlook, By Parenteral (2024-2032) ($MN)
  • Table 15 Global Encephalitis Treatment Market Outlook, By Other routes of Administration (2024-2032) ($MN)
  • Table 16 Global Encephalitis Treatment Market Outlook, By Causative Agent (2024-2032) ($MN)
  • Table 17 Global Encephalitis Treatment Market Outlook, By Viral (2024-2032) ($MN)
  • Table 18 Global Encephalitis Treatment Market Outlook, By Autoimmune (2024-2032) ($MN)
  • Table 19 Global Encephalitis Treatment Market Outlook, By Bacterial (2024-2032) ($MN)
  • Table 20 Global Encephalitis Treatment Market Outlook, By Other Pathogens (2024-2032) ($MN)
  • Table 21 Global Encephalitis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 22 Global Encephalitis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 23 Global Encephalitis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 24 Global Encephalitis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 25 Global Encephalitis Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 26 Global Encephalitis Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 27 Global Encephalitis Treatment Market Outlook, By Research Centers (2024-2032) ($MN)
  • Table 28 Global Encephalitis Treatment Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 29 Global Encephalitis Treatment Market Outlook, By Specialty Centers (2024-2032) ($MN)
  • Table 30 Global Encephalitis Treatment Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.